MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $126.54M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.93M
Average 0.98M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -0.1% | -4.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.1% over three years. Forward estimates point to Revenue at -4.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | $2.54 | Not rated | -7.1 | +82.81% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +132.14% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $180.57M | $3.06 | Not rated | -2.6 | +49.28% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -13.49% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $167.05M | $1.70 | Not rated | -2.1 | +2.26% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | $3.71 | Not rated | 1.4 | +58.37% |
Coya Therapeutics, Inc. NASDAQ:COYA | $73.42M | $3.13 | Not rated | -3.9 | -48.53% |
Clene Inc. NASDAQ:CLNN | $56.45M | $3.92 | Not rated | -2.1 | -59.54% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -74.53% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | $0.18 | Not rated | -1.5 | -40.77% |
Continue the stock analysis
Jump to another research area for this company.